Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Total number of adverse events patient interview · patients with pain management in rheumatoid arthritis
It is very uncertain whether tricyclic antidepressant changes total number of adverse events patient interview compared with control (very low certainty).
1 finding from 1 review
Adverse events (disease‐related: all physical symptoms); · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
It is very uncertain whether tricyclic antidepressant changes number of Withdrawals due to Adverse Events patient interview compared with control (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events (delirium during hospitalisation) · adults with dementia following hip fracture surgery
It is very uncertain whether geriatrician‐led inpatient management changes adverse events (delirium during hospitalisation) compared with orthopaedic‐led inpatient management (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: bronchoconstriction · children and adults with cystic fibrosis
1 finding from 1 review
Serious adverse events participant and study investigator reported · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in serious adverse events participant and study investigator reported compared with skim milk & lactose powder (low certainty).
1 finding from 1 review
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of serious adverse events ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: psychological disorders · adults with chronic neuropathic pain
1 finding from 1 review
Number of participants experiencing muscle‐related adverse events: e.g. soreness, discomfort, cramps, pain · men with urinary incontinence following prostate surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing surface or skin‐related adverse events: e.g. skin reactions, bruising, hypersensitivity to gel · men with urinary incontinence following prostate surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AEs; adverse drug reaction): atrioventricular block · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): atrioventricular block compared with mexiletine (very low certainty).
1 finding from 1 review
Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Withdrawn for medical reasons: Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
The intervention leads to higher adverse events ‐ Withdrawn for medical reasons: Tricyclics versus… (high certainty).
1 finding from 1 review
Neuropsychiatric adverse event · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): neuropsychiatric… compared with propafenone (very low certainty).
1 finding from 1 review
Number of participants with adverse events (epigastric pain, nausea, diarrhoea) · patients with the need for management of diverticulitis
5‐ASA showed no clear difference in number of participants with adverse events (epigastric pain, nausea,… compared with control (all trials) (moderate certainty).
1 finding from 1 review